Categories: Health

Bharat Biotech’s Covaxin proves 93.4% effective against Covid-19, works against Delta variant too

<p>
Phase-III trials of the India-made Covaxin vaccine show that it is 93.4% effective against severe symptomatic COVID-19 and works against the Delta variant as well, Hyderabad- based pharma firm Bharat Biotech announced on Saturday.</p>
<p>
The data demonstrated 65.2% protection against the Delta variant, first identified in India, that led to a surge in infections during the second wave in April and May. The variant is also on the rise in countries such as the US and Europe.</p>
<p>
India's home-grown vaccine manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and Indian Institute of Virology, also showed an effectiveness of 77.8% against symptomatic COVID-19 in the trial.</p>
<p>
<strong>Also read: </strong> <a href="https://www.indianarrative.com/health-news/who-approval-for-bharat-biotech-s-covaxin-likely-in-mid-august-99354.html">WHO approval for Bharat Biotech’s Covaxin likely in mid-August</a></p>
<p>
The Phase-III data came as Ocugen Inc , which is co-developing Covaxin with Bharat Biotech for the U.S. market, prepares to file a request for full U.S. approval.</p>
<p>
Bharat Biotech also said the safety analysis for Covaxin demonstrates adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events.</p>
<p>
Bharat Biotech which has been making 10 million doses of Covaxin a month will now step up production to 23 million doses a month. Besides, the government has asked five public sector companies to start producing the vaccine as well so that it can be made more widely available under the accelerated vaccination drive.</p>
<p>
<strong>Also read:</strong>  <a href="https://www.indianarrative.com/health-news/zydus-seeks-govt-nod-for-use-of-new-india-made-vaccine-as-trials-have-been-completed-99201.html">Zydus seeks govt nod for use of new India-made vaccine as trials have been completed</a></p>
<p>
Last month, vaccine maker AstraZeneca Plc also said its vaccine was effective against the Delta and Kappa variants, citing a study.</p>
<p>
India has been administering the AstraZeneca vaccine, made domestically by the Serum Institute of India under the Covishield brand. While 70 million doses a month of the vaccine are being currently manufactured, the output will be increased to around nearly 100 million doses in July .</p>
<p>
 </p>
<p>
 </p>

IN Bureau

Recent Posts

Russia, Belarus to strengthen cooperation within BRICS, EAEU frameworks

Moscow hosted high-level talks between Russian Foreign Minister Sergey Lavrov and his Belarusian counterpart, Maksim…

1 hour ago

Plane Crash: UK envoy Cameron meets PM Modi, says “UK and India working together to establish facts”

British High Commissioner to India, Lindy Cameron, held a meeting with Prime Minister Narendra Modi…

3 hours ago

“Over 200 diarrhoea cases reported in Jajpur,” says Director of Public Health for Odisha govt

Director of Public Health, Odisha, Dr Nilakantha Mishra, said on Friday that there is a…

5 hours ago

India urges Iran and Israel to avoid escalation, emphasises dialogue and diplomacy

India on Friday expressed deep concern over the recent developments between Iran and Israel and…

7 hours ago

India, China agree to rebuild ties with focus on people-centric engagements

Foreign Secretary Vikram Misri met Chinese Vice Foreign Minister Sun Weidong in New Delhi on…

8 hours ago

Gujarat: PM Modi meets lone survivor of AI-171 flight crash, other injured at Ahmedabad hospital

Prime Minister Narendra Modi on Friday visited the Ahmedabad Civil Hospital and met with Vishwashkumar…

8 hours ago